Innate Pharma receives a milestone payment for IPH 2201, a monoclonal antibody licensed to Novo Nordisk A/S.

Innate Pharma announced that a European trial application has been filed by Novo Nordisk A/S for IPH 2201 (NN8765). This triggered the payment to Innate Pharma of a significant undisclosed milestone. IPH2201 is a humanized antibody generated in the collaboration between Innate Pharma and Novo Nordisk A/S and developed to treat patients with chronic inflammatory and auto-immune diseases. IPH 2201 is the third monoclonal antibody resulting from collaboration with Novo Nordisk A/S expected to enter human clinical trials soon, after IPH 2101 and NN8555. IPH 2201 is a humanised monoclonal antibody developed to treat patients with inflammatory conditions and …